Freyr supports pharmaceutical companies preparing for Japan’s mandatory eCTD v4.0 rollout by 2026 by providing full end-to-end assistance: from dossier conversion and metadata mapping to validation, submission to PMDA, post-submission support, and in-house team training. Our local experts alongside AI-powered tools ensure that your submissions meet strict Japanese requirements to avoi... https://japan.freyrsolutions.com/freyr-japan-pmda-ectd-v4-0-submissions-services-and-solutions